glp-1-rezeptoragonisten Der Ticker: Neues zu – Teil 3 Frühgeburtsrisiko von GLP‑1‑RA in der

Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a

Diabetes/Metabolism Research and Reviews, 35, e3082

The most commonly reported flu-like manifestations include: Nausea and general malaise the most frequent side effect, with incidence varying by product and dose (ranging from approximately 15-40% depending on the specific medication and dosage) Fatigue and low energy levels often described as feeling generally unwell or 'run down' Headaches ranging from mild to moderate intensity Dizziness or light-headedness particularly when standing up quickly, which may reflect dehydration or, in patients also taking insulin or sulfonylureas, possible hypoglycaemia Loss of appetite which, whilst therapeutically beneficial, can contribute to feeling unwell Mild gastrointestinal upset including occasional vomiting or abdominal discomfort These symptoms typically emerge because GLP-1 medications significantly alter gastrointestinal function and metabolic processes

RETURN POLICY

Despite minor fluctuations, the number of AE reports for DPP-4 inhibitors has remained low in recent years